The evaluation of Pentoxifylline efficacy on Adhesive Capsulitis

Evaluation the efficacy of Pentoxifylline and placebo on Adhesive Capsulitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20181103041531N1

Enrollment

Registered

2019-02-28

Start date

2019-01-21

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adhesive capsulitis. Adhesive capsulitis of shoulder

Interventions

Intervention 1: Intervention group: In this group pentoxifylline, oral tablet 400mg which is produced by Amin pharmaceutical company is prescribed twice daily for 3 months. Intervention 2: Control gro

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: diagnosis of adhesive capsulitis is made by a Rheumatologist informed contest is obtained

Exclusion criteria

Exclusion criteria: patient dissatisfaction adhesive capsulitis secondary to malignancy history of cardiac arhythmia history of NSAID use pregnancy or lactation

Design outcomes

Primary

Measure	Time frame
Affected shoulder range of motion. Timepoint: before intervention and after intervention, weekly up to 3 months. Method of measurement: physical examination.;Level of TNF-alpha in blood. Timepoint: before intervention and at the end of study. Method of measurement: blood measurement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Leila Mahmoudieh

Shahid Beheshti University of Medical Sciences

l.mahmoudieh@sbmu.ac.ir+98 21 2360 2188

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026